FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027079189> ?p ?o ?g. }

• W2027079189 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCIntroduction: The intratumoral distribution of tumor targeted nanoparticles (NP) is hindered by dense collagen network and highly fibrous interstitium. Use of antifibrotic agents can decrease tumor interstitial fibrosis and promote NP intratumoral distribution. The objective of this study was to evaluate the effect of Telmisartan (TEL, AT1 blocker/PPAR-γ agonist) and Losartan (LOS, AT1 blocker) on NPs intratumoral distribution and anticancer effects in TNBC and lung cancer.Methods: Anticancer effect of TEL (5 mg/kg) and LOS (20 mg/kg) by inhalation and oral route were evaluated using Non-small cell lung cancer (A549 orthotopic and metastatic model) and triple negative breast cancer (TNBC, MDA-MB-231 orthotopic model) in Nu/nu mice. Also, to study intratumoral distribution, fluorescent polystyrene NP (FPNP) were administered intravenously followed by fluorescent microscopy. Tumor fibrous nature was characterized by estimating collagen-1, transforming growth factor beta1 (TGF-β;1) expression by IHC and ELISA. Collagen deposition in the tumor interstitium was studied by Masson's Trichome staining. To correlate the AT1 receptor blockage to anticancer effects, expression of VEGF, cleaved caspase-3, MMP-9 and microvessel densities (CD31) were quantified by IHC and western blotting. Epithelial Mesenchymal transition (EMT) mediated tumor metastasis was characterized by expressions of E-Cadherin and Vimentin.Results: TEL showed significant antitumor effects in both lung and TNBC tumor models. TEL at 1/4th dose produced superior anticancer effects than LOS. Survival rate was extended with TEL compare to LOS & untreated control. Further, Paclitaxel-NP produced better tumor regression in inhalation with TEL compared to single agent treatment and control. The fibrous nature of lung tumors and TNBC was decreased significantly (p<0.05) with TEL and LOS treatment based on expression of collagen-1 and TGF-β;1. This allowed better FPNP distribution into the tumors compared to control. Further, compared to control tumors, LOS and TEL treated group resulted in 5.33 and 14.33 fold increase in NP distribution. Similarly, Paclitaxel-NP distribution was superior in combination with TEL & LOS treatment, which in turn exhibited synergistic anticancer effects. TEL treatment resulted in the decreased metastatic tumor nodules and tumor volumes. The metastatic markers MMP-9 & vimentin levels were significantly decreased (p<0.001) in TEL group compared to LOS & control, suggesting the promising effects of TEL in tumor anti-metastasis. Further, our study also demonstrated the safety of TEL upon inhalation route.Conclusion: Telmisartan showed significant anticancer effects in Lung cancer and TNBC. Telmisartan could be an ideal candidate for combination therapy to improve the NPs intratumoral distribution and anticancer effects in various cancer types.Citation Format: Chandraiah Godugu, Apurva R. Patel, Srujan Marepally, Ravi Doddapaneni, Mandip Singh Sachdeva, Mahavir B. Chougule. Effect of telmisartan on triple negative breast cancer (TNBC) and lung cancer tumor progression and intratumoral distribution of nanoparticles. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2139. doi:10.1158/1538-7445.AM2013-2139" @default.
• W2027079189 created "2016-06-24" @default.
• W2027079189 creator A5001222816 @default.
• W2027079189 creator A5001963134 @default.
• W2027079189 creator A5010688100 @default.
• W2027079189 creator A5020072116 @default.
• W2027079189 creator A5059706529 @default.
• W2027079189 creator A5089864129 @default.
• W2027079189 date "2013-04-15" @default.
• W2027079189 modified "2023-10-02" @default.
• W2027079189 title "Abstract 2139: Effect of telmisartan on triple negative breast cancer (TNBC) and lung cancer tumor progression and intratumoral distribution of nanoparticles." @default.
• W2027079189 doi "https://doi.org/10.1158/1538-7445.am2013-2139" @default.
• W2027079189 hasPublicationYear "2013" @default.
• W2027079189 type Work @default.
• W2027079189 sameAs 2027079189 @default.
• W2027079189 citedByCount "1" @default.
• W2027079189 countsByYear W20270791892023 @default.
• W2027079189 crossrefType "proceedings-article" @default.
• W2027079189 hasAuthorship W2027079189A5001222816 @default.
• W2027079189 hasAuthorship W2027079189A5001963134 @default.
• W2027079189 hasAuthorship W2027079189A5010688100 @default.
• W2027079189 hasAuthorship W2027079189A5020072116 @default.
• W2027079189 hasAuthorship W2027079189A5059706529 @default.
• W2027079189 hasAuthorship W2027079189A5089864129 @default.
• W2027079189 hasConcept C110121322 @default.
• W2027079189 hasConcept C121608353 @default.
• W2027079189 hasConcept C126322002 @default.
• W2027079189 hasConcept C134306372 @default.
• W2027079189 hasConcept C142724271 @default.
• W2027079189 hasConcept C2776256026 @default.
• W2027079189 hasConcept C2779013556 @default.
• W2027079189 hasConcept C2779256057 @default.
• W2027079189 hasConcept C2779716603 @default.
• W2027079189 hasConcept C2780110267 @default.
• W2027079189 hasConcept C33923547 @default.
• W2027079189 hasConcept C502942594 @default.
• W2027079189 hasConcept C530470458 @default.
• W2027079189 hasConcept C71924100 @default.
• W2027079189 hasConcept C76419328 @default.
• W2027079189 hasConcept C84393581 @default.
• W2027079189 hasConceptScore W2027079189C110121322 @default.
• W2027079189 hasConceptScore W2027079189C121608353 @default.
• W2027079189 hasConceptScore W2027079189C126322002 @default.
• W2027079189 hasConceptScore W2027079189C134306372 @default.
• W2027079189 hasConceptScore W2027079189C142724271 @default.
• W2027079189 hasConceptScore W2027079189C2776256026 @default.
• W2027079189 hasConceptScore W2027079189C2779013556 @default.
• W2027079189 hasConceptScore W2027079189C2779256057 @default.
• W2027079189 hasConceptScore W2027079189C2779716603 @default.
• W2027079189 hasConceptScore W2027079189C2780110267 @default.
• W2027079189 hasConceptScore W2027079189C33923547 @default.
• W2027079189 hasConceptScore W2027079189C502942594 @default.
• W2027079189 hasConceptScore W2027079189C530470458 @default.
• W2027079189 hasConceptScore W2027079189C71924100 @default.
• W2027079189 hasConceptScore W2027079189C76419328 @default.
• W2027079189 hasConceptScore W2027079189C84393581 @default.
• W2027079189 hasLocation W20270791891 @default.
• W2027079189 hasOpenAccess W2027079189 @default.
• W2027079189 hasPrimaryLocation W20270791891 @default.
• W2027079189 hasRelatedWork W1497490920 @default.
• W2027079189 hasRelatedWork W1628749276 @default.
• W2027079189 hasRelatedWork W1762036063 @default.
• W2027079189 hasRelatedWork W182881448 @default.
• W2027079189 hasRelatedWork W1871308790 @default.
• W2027079189 hasRelatedWork W1963561230 @default.
• W2027079189 hasRelatedWork W1964780874 @default.
• W2027079189 hasRelatedWork W1964798910 @default.
• W2027079189 hasRelatedWork W1965362737 @default.
• W2027079189 hasRelatedWork W1965729533 @default.
• W2027079189 hasRelatedWork W1489893598 @default.
• W2027079189 hasRelatedWork W1496003888 @default.
• W2027079189 hasRelatedWork W1565892064 @default.
• W2027079189 hasRelatedWork W1600956009 @default.
• W2027079189 hasRelatedWork W1673760034 @default.
• W2027079189 hasRelatedWork W1701215495 @default.
• W2027079189 hasRelatedWork W1820281836 @default.
• W2027079189 hasRelatedWork W1925830111 @default.
• W2027079189 hasRelatedWork W1946610084 @default.
• W2027079189 hasRelatedWork W2284116582 @default.
• W2027079189 isParatext "false" @default.
• W2027079189 isRetracted "false" @default.
• W2027079189 magId "2027079189" @default.
• W2027079189 workType "article" @default.